Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Health Services Research & Development

Go to the ORD website
Go to the QUERI website

HSR&D Citation Abstract

Search | Search by Center | Search by Source | Keywords in Title

Physician and patient influences on provider performance: ß-blockers in postmyocardial infarction management in the MI-Plus study.

Funkhouser E, Houston TK, Levine DA, Richman J, Allison JJ, Kiefe CI. Physician and patient influences on provider performance: ß-blockers in postmyocardial infarction management in the MI-Plus study. Circulation. Cardiovascular quality and outcomes. 2011 Jan 1; 4(1):99-106.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.
   Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions



Abstract:

BACKGROUND: Efforts to improve the quality of care for patients with cardiovascular disease frequently target the decrease of physician-level performance variability. We assessed how variability in providing -blockers to ambulatory postmyocardial infarction (MI) patients was influenced by physician and patient level characteristics. METHODS AND RESULTS: -Blocker prescription and patient characteristics were abstracted from charts of post-MI patients treated by 133 primary care physicians between 2003 and 2007 and linked to physician and practice characteristics. Associations of -blocker prescription with physician- and patient-level characteristics were examined using mixed-effects models, with physician-level effects as random. Mean physician-specific predicted probabilities and the intraclass correlations, which assessed the proportion of variance explainable at the physician level, were estimated. Of 1901 patients without major contraindication, 69.1% (range across physicians, 20% to 100%) were prescribed -blockers. Prescription varied with comorbidity from 78.3% in patients with chronic kidney disease to 54.7% for patients with stroke. Although physician characteristics such as older physician age, group practice, and rural location were each positively associated with -blocker prescription, physician factors accounted for only 5% to 8% of the variance in -blocker prescription; the preponderance of the variance, 92% to 95%, was at the patient level. The mean physician-specific probability of -blocker prescription (95% confidence interval) in the fully adjusted model was 63% (61% to 65%). CONCLUSIONS: -Blocker prescription rates were surprisingly low. The contribution of physician factors to overall variability in -blocker prescription, however, was limited. Increasing evidence-based use of -blockers may not be accomplished by focusing mostly on differential performance across physicians.





Questions about the HSR&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.